COEP vs. OKYO, ACHL, NKGN, CYTH, QNCX, ESLA, INKT, SRZN, PLUR, and BCLI
Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include OKYO Pharma (OKYO), Achilles Therapeutics (ACHL), NKGen Biotech (NKGN), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Surrozen (SRZN), Pluri (PLUR), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry.
OKYO Pharma (NASDAQ:OKYO) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
OKYO Pharma presently has a consensus price target of $7.00, indicating a potential upside of 451.18%. Coeptis Therapeutics has a consensus price target of $3.00, indicating a potential upside of 935.91%. Given OKYO Pharma's higher possible upside, analysts clearly believe Coeptis Therapeutics is more favorable than OKYO Pharma.
In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.
Coeptis Therapeutics received 1 more outperform votes than OKYO Pharma when rated by MarketBeat users.
Coeptis Therapeutics' return on equity of 0.00% beat OKYO Pharma's return on equity.
3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
OKYO Pharma has higher earnings, but lower revenue than Coeptis Therapeutics.
OKYO Pharma has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500.
Summary
OKYO Pharma beats Coeptis Therapeutics on 5 of the 9 factors compared between the two stocks.
Get Coeptis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coeptis Therapeutics Competitors List
Related Companies and Tools
